Clinical Trial Update: Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors [Phase 2, Phase 3]

View source ↗

Summary

A Neoadjuvant combination therapy trial using doxorubicin, cisplatin, and methotrexate in young adults with primary bone tumors has reported Phase 2 and Phase 3…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms Connective Tissue
• Neoplasms Connective and Soft Tissue
• Osteosarcoma
• Sarcoma
• Sarcoma of Bone

Drugs mentioned

• CISPLATIN (cisplatin)
• Doxorubicin (doxorubicin)
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Blokhin's Russian Cancer Research Center | Conditions: Osteosarcoma, Neoplasms, Connective Tissue | Phase 2, Phase 3 | Status: UNKNOWN